Why is investing in drugs to treat rare diseases an attractive investment for drug companies?
If you were a drug manufacturer, you naturally would want to focus your research on more common, highly prevalent diseases. If there are more patients […]
If you were a drug manufacturer, you naturally would want to focus your research on more common, highly prevalent diseases. If there are more patients […]
Prof Gillian Leng’s replacement as chief executive of the National Institute for Health and Care Excellence (NICE) has been named as Dr Samantha Roberts, currently […]
NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to access treatment with Alexion’s Ultomiris, ahead of […]
Intellimed Healthcare Solutions organized an online webinar on “Health Economics and Outcomes Research/ Health Technology Assessment: The evolving role in the Indian Healthcare Ecosystem” on […]
Intellimed in collaboration with alpha MD & IMPA along with PharmaShots as the media partner is gladly organizing a webinar on “Health Economics & Outcomes […]
With exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are Excellence (NICE), Leela Barham takes a look […]
Copyright © 2024 | WordPress Theme by MH Themes